Finding the right talent is challenging for any organization in any industry, but when you work in a complex field that requires highly skilled workers, it can be even more difficult. BioAgilytix’s CEO discusses the critical nature of hiring for a CRO, and approaches to attracting and retaining top scientific talent in a competitive industry.
In this Q&A session, we speak to Beth Heinz, Executive Director of Global Business Development and Key Accounts at BioAgilytix, as she discusses the evolution of her career with BioAgilytix and the opportunities she sees coming as the industry continues to advance.
It is anticipated that biologics will comprise 50% of the top 100 drugs by 2021. But, given the structural complexities of large molecule drugs, adherence to stringent quality standards will be a necessary part of effectively bringing these innovations to market. We discuss why it will be essential for pharma and biotech companies to align with outsourced partners that can deliver the quality science large molecule bioanalysis demands.
In our latest Team Q&A session, we talk to Isabel Bernges, Project Manager & Study Coordinator at BioAgilytix Europe, as she explains what her typical work day involves and why she enjoys the interdisciplinary collaboration of her role.
Our team recently attended the 14th Annual PEGS Summit to participate in discussions around advancements in biotherapeutic protein drug development and how they impact the work we do with large molecule biologics. From improving efficacy of CAR-T cell therapies to managing the challenges of immunogenicity testing, we’ve summarized the most compelling insights we gained at this year’s event.
BioAgilytix recently had the opportunity to work on a particularly difficult clinical phase anti-drug antibody (ADA) assessment for an innovative PEGylated drug therapy designed to treat a serious chronic condition. Jeff Sailstad, our USA Chief Scientific Officer, explains how our team approached the unique challenges of this assessment.
In this Q&A session, we get to know William Hunter, Director of Business Development and Global Key Accounts at BioAgilytix Europe, as he discusses why he moved to Germany for his role and what he sees coming for BioAgilytix in the industry.
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). CAR-T cells have demonstrated clinical efficacy in hematologic malignancies and targeting solid tumors. However, CAR-T therapy also can elicit cytokine release syndrome (CRS) cytotoxicity. This unwanted release of cytokines has also been seen following the infusion of therapeutic monoclonal antibodies (mAbs), systemic interleukin-2 (IL-2), and the bispecific CD19-CD3 T-cell engaging antibody blinatumomab.
In this Q&A session, we get to know Florian Sieglitz, Principal Investigator / Bioanalytical Project Manager (BPM) at BioAgilytix Europe, as he discusses his experiences working in drug development and how his role with BioAgilytix Europe is growing along with the company.
Scientists from BioAgilytix recently attended the 12th WRIB in Philadelphia, PA. Meeting new contacts in the industry and taking part in discussions concerning the most innovative topics in bioanalysis, biomarkers, and immunogenicity was a genuinely valuable and enjoyable experience. We recap the topics that our team found to be most interesting at WRIB this year.
Services
Platforms
